These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17940191)

  • 1. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
    Einstein M; Akiyama TE; Castriota GA; Wang CF; McKeever B; Mosley RT; Becker JW; Moller DE; Meinke PT; Wood HB; Berger JP
    Mol Pharmacol; 2008 Jan; 73(1):62-74. PubMed ID: 17940191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
    Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
    Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
    J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
    J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
    Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
    Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhodanine derivatives as novel peroxisome proliferator-activated receptor gamma agonists.
    Liu Q; Zhang YY; Lu HL; Li QY; Zhou CH; Wang MW
    Acta Pharmacol Sin; 2007 Dec; 28(12):2033-9. PubMed ID: 18031620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible ligand recognition of peroxisome proliferator-activated receptor-gamma (PPARgamma).
    Yamagishi K; Yamamoto K; Mochizuki Y; Nakano T; Yamada S; Tokiwa H
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3344-7. PubMed ID: 20444603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The conserved residue Phe273(282) of PPARalpha(gamma), beyond the ligand-binding site, functions in binding affinity through solvation effect.
    Yue L; Ye F; Xu X; Shen J; Chen K; Shen X; Jiang H
    Biochimie; 2005 Jun; 87(6):539-50. PubMed ID: 15935279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fluorescent indicator to visualize ligand-induced receptor/coactivator interactions for screening of peroxisome proliferator-activated receptor gamma ligands in living cells.
    Awais M; Sato M; Umezawa Y
    Biosens Bioelectron; 2007 May; 22(11):2564-9. PubMed ID: 17095203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.
    Ahn JH; Shin MS; Jung SH; Kang SK; Kim KR; Rhee SD; Jung WH; Yang SD; Kim SJ; Woo JR; Lee JH; Cheon HG; Kim SS
    J Med Chem; 2006 Jul; 49(15):4781-4. PubMed ID: 16854085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
    Sheu SH; Kaya T; Waxman DJ; Vajda S
    Biochemistry; 2005 Feb; 44(4):1193-209. PubMed ID: 15667213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial agonists activate PPARgamma using a helix 12 independent mechanism.
    Bruning JB; Chalmers MJ; Prasad S; Busby SA; Kamenecka TM; He Y; Nettles KW; Griffin PR
    Structure; 2007 Oct; 15(10):1258-71. PubMed ID: 17937915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
    Geese WJ; Achanzar W; Rubin C; Hariharan N; Cheng P; Tomlinson L; Ordway N; Dracopoli NC; Delmonte T; Hui L; Krishnan B; Cosma G; Ranade K
    Pharmacogenet Genomics; 2008 Oct; 18(10):903-10. PubMed ID: 18794727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.
    Thieme TM; Steri R; Proschak E; Paulke A; Schneider G; Schubert-Zsilavecz M
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2469-73. PubMed ID: 20307981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner.
    Bonofiglio D; Qi H; Gabriele S; Catalano S; Aquila S; Belmonte M; Andò S
    Endocr Relat Cancer; 2008 Jun; 15(2):545-57. PubMed ID: 18509005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
    Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
    Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.